KR20200109026A - COMPOSITION FOR IMPROVING IMMUNITY FUNCTION COMPRISING Daphne genkwa AND Euphorbiakansui Liou ex Wanga COMPLEX EXTRACT AS AN EFFECTIVE INGREDIENT - Google Patents
COMPOSITION FOR IMPROVING IMMUNITY FUNCTION COMPRISING Daphne genkwa AND Euphorbiakansui Liou ex Wanga COMPLEX EXTRACT AS AN EFFECTIVE INGREDIENT Download PDFInfo
- Publication number
- KR20200109026A KR20200109026A KR1020190027981A KR20190027981A KR20200109026A KR 20200109026 A KR20200109026 A KR 20200109026A KR 1020190027981 A KR1020190027981 A KR 1020190027981A KR 20190027981 A KR20190027981 A KR 20190027981A KR 20200109026 A KR20200109026 A KR 20200109026A
- Authority
- KR
- South Korea
- Prior art keywords
- red bean
- persimmon
- extract
- immune function
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 241001310717 Daphne genkwa Species 0.000 title abstract description 4
- 241000701408 Euphorbia kansui Species 0.000 title abstract description 4
- 230000036039 immunity Effects 0.000 title description 6
- 239000004615 ingredient Substances 0.000 title description 3
- 230000036737 immune function Effects 0.000 claims abstract description 35
- 235000013305 food Nutrition 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 230000002708 enhancing effect Effects 0.000 claims abstract description 17
- 240000001417 Vigna umbellata Species 0.000 claims description 127
- 235000011453 Vigna umbellata Nutrition 0.000 claims description 127
- 235000011511 Diospyros Nutrition 0.000 claims description 78
- 244000236655 Diospyros kaki Species 0.000 claims description 77
- 229940027779 persimmon extract Drugs 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 229940069765 bean extract Drugs 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 8
- OAQWWRSICWQQSE-UHFFFAOYSA-N octan-2-yl 16-methylheptadecanoate Chemical compound CCCCCCC(C)OC(=O)CCCCCCCCCCCCCCC(C)C OAQWWRSICWQQSE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 abstract description 10
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 239000003960 organic solvent Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 229940124622 immune-modulator drug Drugs 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- -1 fluoroalkane Chemical compound 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000006089 Phaseolus angularis Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 240000007098 Vigna angularis Species 0.000 description 1
- 235000010711 Vigna angularis Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 면역기능 증진용 조성물에 관한 것으로, 더욱 상세하게는 팥꽃나무 및 감수 복합 추출물을 유효성분으로 포함하는 면역기능 증진용 약학 또는 식품 조성물에 관한 것이다.The present invention relates to a composition for enhancing immune function, and more particularly, to a pharmaceutical or food composition for enhancing immune function, comprising a red bean and persimmon complex extract as an active ingredient.
일반적으로 면역반응이란, 외부에서 우리 몸으로 들어오는 모든 물질에 대해서 나타나는 반응을 말한다. 특히 살아있는 생명체인 미생물들이 질병의 발생과 직접적으로 또는 간접적으로 관련되어 있기 때문에, 이들에 대한 면역반응이 숙주에게 매우 중요하다. 우리몸의 면역체계가 외부에서 침투한 미생물들을 효과적으로 제거하거나 억제하지 못하게 되면, 침투한 미생물들은 우리 몸에서 증식하여 질병을 일으킬 수도 있다. In general, the immune response refers to a reaction that occurs to all substances entering our body from the outside. In particular, because microorganisms, which are living organisms, are directly or indirectly related to the occurrence of diseases, the immune response against them is very important to the host. When the body's immune system cannot effectively remove or suppress the microbes that have penetrated from the outside, the microbes that have penetrated can multiply in the body and cause disease.
사람에 있어서의 면역기전은 피부와 같이 외부의 침입을 저지하는 역할을 하는 1차 방어선이 있으며, 자연면역체계(선천적 면역)와 획득면역체계(후천적 면역)로 분류되는 2차 방어선이 존재한다. 자연 면역체계(선천적 면역)의 화학적 방어로는 침입 당한 세포가 침입한 미생물을 죽이거나 히스타민(histamine), 키닌(kinin), 보완제(complement), 인터페론(interferon)과 같은 화학물질을 분비하여 방어하고 면역세포 등을 유도하는 등 침입 속도를 줄이는 작용을 한다. 자연 면역체계의 세포적 방어로는 백혈구의 종류인 식세포(산성백혈구, 중성백혈구, 단핵구)와 림프구 중의 하나인 자연살해 세포(NK세포)들이 침입한 미생물을 공격한다. 이 중 단핵구는 상처부위에 도달하면 커다란 대식세포(macrophage)로 성장하게 되는데 자연킬러세포와 함께 방어기 전의 가장 중추적인 역할을 담당하게 된다. The immune mechanism in humans has a primary line of defense, such as skin, that serves to block external invasion, and there are secondary lines of defense classified into natural immune systems (innate immunity) and acquired immune systems (acquired immunity). Chemical defense of the natural immune system (innate immunity) is defense by invading cells by killing invading microorganisms or by secreting chemicals such as histamine, kinin, complement, and interferon. It acts to reduce the rate of invasion, such as inducing immune cells. As a cellular defense of the natural immune system, phagocytes (acid leukocytes, neutrophils, monocytes), which are types of white blood cells, and natural killer cells (NK cells), which are one of lymphocytes, attack the invading microorganisms. Among these, monocytes grow into large macrophages when they reach the wound site, and play the most pivotal role before the defense mechanism together with natural killer cells.
현대 사회가 복잡해지고 발전된 산업으로 인한 여러 돌연변이 발생 원인이 생활공간 가까이 접근되어 있고, 그러한 돌연변이 발생 원인으로 인해 인체의 정상 유전자나 바이러스 등의 유전자의 변형이 더욱 가속화되었다. 결국 약품은 발전하였지만 면역세포는 유전자의 변형으로 인하여 그 기능이 약화되고 바이러스는 더욱 강해져 더욱더 많은 문제를 발생시키고 있다. 이와 같이 현대인의 식습관이나 환경의 오염으로 인한 면역력 저하는 더 강해진 바이러스, 외부의 미생물 등의 침입에 의해 야기되는 홍역과 독감들의 전염성 질환, 암, 선천성기형, 면역계 결함 및 많은 치명적 질병에 쉽게 노출되는 결과를 초래한다. The modern society has become complicated and many causes of mutations caused by advanced industries are approaching living spaces, and such mutations have further accelerated the modification of genes such as normal genes or viruses in the human body. In the end, drugs have developed, but immune cells are weakened due to genetic modification, and viruses become stronger, causing more and more problems. As described above, the decline in immunity due to pollution of the modern diet or environment is easily exposed to infectious diseases of measles and flu, cancer, congenital malformations, immune system defects, and many fatal diseases caused by invasion of stronger viruses and external microorganisms. Has consequences.
면역조절 치료제 시장 규모는 2003년 340억 달러의 시장을 형성하고 있으며, 연평균 성장률 8.2%로 2010년에는 579억 달러의 시장 규모로 전망되었다. 현재 면역조절 치료제의 제품들은 화학적 합성제품보다 바이오 제품의 개발에 더 많은 연구가 진행되고 있는 것으로 파악되며, 바이오 의약품으로의 면역조절 치료제 성장률은 예상하면 10%를 상회할 것으로 전망된다. 한국의 면역조절 치료제 세부기술별 발표건수는 사이토카인 분야에 1,425건으로 가장 많은 논문이 검색되었으며, 백신(339건), 면역 억제 제(149건), 면역증강제(126건) 순으로 관련 논문이 출판되고 있다. 특히, 면역 증강제 분야는 조사기간인 15년 동안 총 126건의 논문이 발표된 것으로 미뤄봤을 때 연구개발 시작 단계로써, 전세계적인 동향 역시 경쟁이 치열하지 않은 분야로 분석된다. 따라서, 면역증강제 분야는 현재까지 많은 연구개발 성과 및 경쟁자가 적은 향후 성장 가능성이 많은 분야라고 할 수 있다. 따라서 다양한 소재의 효과적인 면역 강화제 관련 신규 소재개발에 대한 관심은 더욱더 증가할 것으로 예상된다. The market size of immunomodulatory drugs was formed at $34 billion in 2003, with an annual average growth rate of 8.2%, which is expected to reach $57.9 billion in 2010. Currently, more research is being conducted on the development of bio-products for immunomodulatory drugs than for chemically synthesized products, and the growth rate of immunomodulatory drugs to biopharmaceuticals is expected to exceed 10%. The number of publications by detailed technology for immunomodulatory treatment in Korea was 1,425 in the cytokine field, with the most papers being searched, followed by vaccines (339), immunosuppressants (149), and immune boosters (126). Has become. In particular, the field of immune enhancers is the beginning of research and development, considering that a total of 126 papers have been published during the 15 years of the investigation, and global trends are also analyzed as a field that is not fierce competition. Therefore, the field of immunity enhancing agents can be said to be a field with high potential for future growth with few R&D achievements and competitors. Therefore, interest in the development of new materials related to effective immune enhancing agents of various materials is expected to increase further.
본 발명의 목적은 인체에 유해성이 없는 천연재료를 이용하여 면역기능을 현저히 증진시킬 수 있는 면역기능 증진용 약학 또는 식품 조성물을 제공하는 데 있다.It is an object of the present invention to provide a pharmaceutical or food composition for improving immune function that can significantly enhance immune function using natural materials that are not harmful to the human body.
본 발명의 하나의 측면에 따르면,According to one aspect of the invention,
팥꽃나무 및 감수 복합 추출물을 유효성분으로 포함하는 면역기능 증진용 약학 조성물이 제공된다.There is provided a pharmaceutical composition for improving immune function comprising a red bean and persimmon complex extract as an active ingredient.
상기 팥꽃나무 및 감수 복합 추출물은 팥꽃나무 및 감수를 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출한 것일 수 있다.The red bean and persimmon complex extract may be obtained by extracting red bean and persimmon with water, alcohol having 1-4 carbon atoms, or a mixed solvent thereof.
상기 팥꽃나무 추출물은 팥꽃나무의 줄기 및 뿌리 중에서 선택된 1종 이상의 추출물일 수 있다.The red bean extract may be one or more extracts selected from the stem and root of red bean.
상기 감수 추출물은 감수의 뿌리 추출물일 수 있다.The persimmon extract may be a root extract of persimmon.
바람직하게는 상기 팥꽃나무 및 감수 복합 추출물은 팥꽃나무 추출물 100중량부에 대하여 감수 추출물 50 내지 200중량부를 포함할 수 있고, 더욱 바람직하게는 팥꽃나무 추출물 100중량부에 대하여 감수 추출물 60 내지 130중량부, 더욱 더 바람직하게는 팥꽃나무 추출물 100중량부에 대하여 감수 추출물 80 내지 110중량부를 포함할 수 있다.Preferably, the red bean and persimmon complex extract may contain 50 to 200 parts by weight of persimmon extract based on 100 parts by weight of red bean extract, more preferably 60 to 130 parts by weight of persimmon extract based on 100 parts by weight of red bean extract , More preferably, it may contain 80 to 110 parts by weight of persimmon extract based on 100 parts by weight of red bean extract.
본 발명의 다른 하나의 측면에 따르면,According to another aspect of the present invention,
팥꽃나무 및 감수 복합 추출물을 유효성분으로 포함하는 면역기능 증진용 식품 조성물이 제공된다.There is provided a food composition for improving immune function comprising a red bean and persimmon complex extract as an active ingredient.
상기 팥꽃나무 및 감수 복합 추출물은 팥꽃나무 및 감수를 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출한 것일 수 있다.The red bean and persimmon complex extract may be obtained by extracting red bean and persimmon with water, alcohol having 1-4 carbon atoms, or a mixed solvent thereof.
상기 팥꽃나무 추출물은 팥꽃나무의 줄기 및 뿌리 중에서 선택된 1종 이상의 추출물일 수 있다.The red bean extract may be one or more extracts selected from the stem and root of red bean.
상기 감수 추출물은 감수의 뿌리 추출물일 수 있다.The persimmon extract may be a root extract of persimmon.
바람직하게는 상기 팥꽃나무 및 감수 복합 추출물은 팥꽃나무 추출물 100중량부에 대하여 감수 추출물 50 내지 200중량부를 포함할 수 있고, 더욱 바람직하게는 팥꽃나무 추출물 100중량부에 대하여 감수 추출물 60 내지 130중량부, 더욱 더 바람직하게는 팥꽃나무 추출물 100중량부에 대하여 감수 추출물 80 내지 110중량부를 포함할 수 있다.Preferably, the red bean and persimmon complex extract may contain 50 to 200 parts by weight of persimmon extract based on 100 parts by weight of red bean extract, more preferably 60 to 130 parts by weight of persimmon extract based on 100 parts by weight of red bean extract , More preferably, it may contain 80 to 110 parts by weight of persimmon extract based on 100 parts by weight of red bean extract.
본 발명의 다른 또 하나의 측면에 따르면,According to another aspect of the present invention,
팥꽃나무 및 감수를 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출하여 팥꽃나무 및 감수 복합 추출물을 제조하는 단계를 포함하는 면역기능 증진용 약학 조성물의 제조방법이 제공된다.There is provided a method of preparing a pharmaceutical composition for improving immune function comprising the step of preparing a red bean and persimmon complex extract by extracting red bean and persimmon with water, alcohol having 1-4 carbon atoms, or a mixed solvent thereof.
상기 팥꽃나무는 팥꽃나무의 줄기 및 뿌리 중에서 선택된 1종 이상의 부위를 사용할 수 있다.The red bean flower tree may use one or more parts selected from the stem and root of the red bean flower tree.
상기 감수는 감수의 뿌리 부위를 사용할 수 있다.The persimmon can be used at the root of persimmon.
본 발명의 다른 또 하나의 측면에 따르면,According to another aspect of the present invention,
팥꽃나무 및 감수를 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출하여 팥꽃나무 및 감수 복합 추출물을 제조하는 단계를 포함하는 면역기능 증진용 식품 조성물의 제조방법이 제공된다.There is provided a method for preparing a food composition for enhancing immune function comprising the step of preparing a red bean and persimmon complex extract by extracting red bean and persimmon with water, alcohol having 1-4 carbon atoms, or a mixed solvent thereof.
상기 팥꽃나무는 팥꽃나무의 줄기 및 뿌리 중에서 선택된 1종 이상의 부위를 사용할 수 있다.The red bean flower tree may use one or more parts selected from the stem and root of the red bean flower tree.
상기 감수는 감수의 뿌리 부위를 사용할 수 있다.The persimmon can be used at the root of persimmon.
본 발명의 팥꽃나무 및 감수 복합 추출물을 유효성분으로 포함하는 약학 조성물은 천연 재료를 사용하여 인체에 무해하면서도 단독 재료를 사용한 것에 비하여 면역기능 증강에 현저한 시너지 효과를 나타낼 수 있으므로 NK세포의 면역기능 조절제로서 약학 소재 또는 식품 소재로서 다양하게 활용될 수 있다.The pharmaceutical composition containing the red bean and persimmon complex extract of the present invention as an active ingredient is harmless to the human body by using natural materials and can exhibit a remarkable synergistic effect in enhancing immune function compared to using a single material. As a pharmaceutical material or food material, it can be used in various ways.
도 1은 실험예 1에 따른 면역증진 효과 분석 결과를 나타낸 것이다.
도 2 및 도 3은 실험예 2에 따른 면역증진 시너지 효과 분석 결과를 나타낸 것이다.1 shows the results of analysis of the immunity enhancing effect according to Experimental Example 1.
2 and 3 show the results of analyzing the synergistic effect of increasing immunity according to Experimental Example 2.
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 도면에 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.
Since the present invention can apply various transformations and have various embodiments, specific embodiments are illustrated in the drawings and will be described in detail in the detailed description. However, this is not intended to limit the present invention to a specific embodiment, it is to be understood to include all conversions, equivalents, and substitutes included in the spirit and scope of the present invention. In describing the present invention, when it is determined that a detailed description of a related known technology may obscure the subject matter of the present invention, a detailed description thereof will be omitted.
본 발명에서 ‘복합 추출물’은 1) 팥꽃나무 추출물과 감수 추출물의 혼합 형태, 또는 2) 팥꽃나무 조직과 감수의 조직을 먼저 혼합한 후 이를 추출한 형태를 의미한다.In the present invention, “composite extract” refers to 1) a mixed form of red bean extract and persimmon extract, or 2) a form obtained by first mixing the red bean and persimmon tissues and then extracting them.
본 발명에서 ‘팥꽃나무(Daphne genkwa)’는 쌍떡잎식물 도금양목 팥꽃나무과의 낙엽관목을 의미한다.In the present invention, "Daphne genkwa" refers to a deciduous shrub of the apricot family, a dicotyledonous plant.
본 발명에서 ‘팥꽃나무 추출물’은 팥꽃나무의 뿌리, 줄기, 잎, 꽃 등 모든 식물 조직에서 추출한 추출물일 수 있고, 바람직하게는 팥꽃나무의 지상부를 추출한 추출물을 의미한다.In the present invention, the'red bean extract' may be an extract extracted from all plant tissues such as roots, stems, leaves, and flowers of red bean, and preferably refers to an extract obtained by extracting the upper part of the red bean.
또한, 본 발명에서 ‘감수(Euphorbiakansui Liou ex Wanga)’는 대극과(Euphorbiaceae)에 속하는 다년생 초본으로서 한국, 일본 등에 주로 분포하는 것을 의미한다.In addition, in the present invention,'gamsu (Euphorbiakansui Liou ex Wanga)' refers to a perennial herb belonging to the Euphorbiaceae family and mainly distributed in Korea and Japan.
본 발명에서 ‘감수 추출물’은 뿌리, 줄기, 잎, 꽃 등 모든 식물 조직에서 추출한 추출물일 수 있고, 바람직하게는 감수의 덩이뿌리에서 추출한 추출물을 의미한다.In the present invention, the'persimmon extract' may be an extract extracted from all plant tissues such as roots, stems, leaves, flowers, etc., and preferably means an extract extracted from tubers of persimmon.
본 발명에 있어서, 상기 팥꽃나무 및 감수 추출물은 물, 유기용매 또는 이들의 혼합물을 추출 용매로서 이용하여 추출된 것일 수 있다. 이때 사용되는 유기용매의 종류나 물과 유기용매의 혼합 비율은 특별히 제한되지 않는다. In the present invention, the red bean and persimmon extract may be extracted using water, an organic solvent, or a mixture thereof as an extraction solvent. At this time, the type of the organic solvent used or the mixing ratio of water and the organic solvent is not particularly limited.
예를 들어, 상기 유기용매는 저급 알코올, 헥산, 아세톤, 에틸 아세테이트, 클로로포름, 및 디에틸에테르로 이루어진 군으로부터 선택된 하나 이상의 용매일 수 있다. 상기 저급 알코올은 탄소수 1 내지 6의 알코올일 수 있다. 예를 들어, 저급 알코올로는 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜 등을 이용할 수 있다. 유기용매는 이 외에도 아세트산, DMFO(dimethyl-formamide), DMSO(dimethyl sulfoxide) 등의 극성 용매, 아세토나이트릴, 에틸 아세테이트, 메틸 아세테이트, 플루오로알칸, 펜탄, 2,2,4-트리메틸펜탄, 데칸, 사이클로헥산, 사이클로펜탄, 디이소부틸렌, 1-펜텐, 1-클로로부탄, 1-클로로펜탄, o-자일렌, 디이소프로필 에테르, 2-클로로프로판, 톨루엔, 1-클로로프로판, 클로로벤젠, 벤젠, 디에틸 에테르, 디에틸 설파이드, 클로로포름, 디클로로메탄, 1,2-디클로로에탄, 어닐린, 디에틸아민, 에테르, 사염화탄소 및 THF(Tetrahydrofuran) 등의 비극성 용매를 사용할 수도 있다.For example, the organic solvent may be one or more solvents selected from the group consisting of lower alcohol, hexane, acetone, ethyl acetate, chloroform, and diethyl ether. The lower alcohol may be an alcohol having 1 to 6 carbon atoms. For example, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol, or ethylene glycol may be used as the lower alcohol. In addition to organic solvents, polar solvents such as acetic acid, dimethyl-formamide (DMFO), and dimethyl sulfoxide (DMSO), acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, 2,2,4-trimethylpentane, decane , Cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene , Benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and non-polar solvents such as THF (Tetrahydrofuran) may be used.
하기 실시예에서 확인할 수 있는 바와 같이, 팥꽃나무 및 감수를 유기용매로 추출할 경우 팥꽃나무 및 감수 추출물은 상층액과 하층액으로 분리되는데, 상층액은 팥꽃나무 및 감수 추출물의 오일 분획이며, 하층액은 일반적인 용매 추출물에 해당한다. 하층액을 다시 원심분리 또는 여과지를 통해 분리하면 액상과 고형 상태의 잔사로 나눠지는데 이때의 잔사는 팥꽃나무 및 감수 추출물의 왁스 분획이다. 따라서, 본 발명의 팥꽃나무 및 감수 추출물은 팥꽃나무 및 감수 추출물의 오일 분획, 팥꽃나무 및 감수 추출물의 액상 분획, 팥꽃나무 및 감수 추출물의 왁스 분획을 모두 포함하는 개념으로 해석된다. 한 구체예에서, 상기 팥꽃나무 및 감수 추출물은 팥꽃나무 및 감수 추출물의 오일 분획, 팥꽃나무 및 감수 추출물의 액상 분획 및 팥꽃나무 및 감수 추출물의 왁스 분획으로 이루어진 군으로부터 선택된 어느 하나 이상을 포함할 수 있다.As can be seen in the following examples, when extracting red bean and persimmon trees with an organic solvent, red bean and persimmon extracts are separated into a supernatant and a lower layer, and the supernatant is an oil fraction of red bean and persimmon extracts, and the lower layer The liquid corresponds to a common solvent extract. When the lower layer is separated again through centrifugation or filter paper, it is divided into liquid and solid residues, which are the wax fractions of red bean and persimmon extracts. Therefore, the azuki bean and persimmon extract of the present invention is interpreted as a concept including all of the oil fraction of the red bean and persimmon extract, the liquid fraction of the red bean and persimmon extract, and the wax fraction of the red bean and persimmon extract. In one embodiment, the red bean and persimmon extract may include any one or more selected from the group consisting of the oil fraction of red bean and persimmon extract, the liquid fraction of red bean and persimmon extract, and the wax fraction of red bean and persimmon extract. have.
한 구체예에서, 상기 팥꽃나무 및 감수 추출물은 팥꽃나무 및 감수의 저급 알코올 추출물일 수 있으며, 바람직하게는 팥꽃나무 및 감수의 에탄올 추출물일 수 있다.In one embodiment, the red bean and persimmon extract may be a lower alcohol extract of red bean and persimmon, preferably ethanol extract of red bean and persimmon.
본 명세서에서 사용되는 용어 ‘추출물’은 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 팥꽃나무 및 감수 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 또한, 상기 추출물이나 분획물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 팥꽃나무 및 감수 추출물에 포함된다.The term “extract” as used herein also includes a fraction obtained by further fractionating the extract. That is, the red bean and persimmon extracts include not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. In addition, the extract or fraction obtained by passing through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through various purification methods are also included in the red bean and persimmon extracts of the present invention.
한 구체예에서, 상기 팥꽃나무 및 감수 추출물은 팥꽃나무 및 감수의 유기용매 추출물을 제2의 유기용매로 재분획한 분획물일 수 있다. 여기에서, 팥꽃나무 및 감수의 유기용매 추출물이라 함은 광의로는 앞서 설명한 팥꽃나무 및 감수 추출물의 오일 분획, 팥꽃나무 및 감수 추출물의 액상 분획, 팥꽃나무 및 감수 추출물의 왁스 분획을 모두 포함하며, 협의로는 이 중 팥꽃나무 및 감수 추출물의 액상 분획을 의미한다. 그러므로, 한 구체예에서, 상기 팥꽃나무 및 감수의 유기 추출물을 제2의 유기용매로 재분획한 분획물은 팥꽃나무 및 감수 추출물의 액상 분획을 제2의 유기 용매로 재분획한 분획물을 의미할 수 있다. 다른 구체예에서, 상기 팥꽃나무 및 감수 추출물은 팥꽃나무 및 감수의 저급 알코올 추출물을 제2의 유기용매로 재분획한 분획물일 수 있다. 또 다른 구체예에서, 상기 팥꽃나무 및 감수 추출물은 팥꽃나무 및 감수의 에탄올 추출물을 헥산으로 재분획한 분획물일 수 있다. 하기 실시예에서 살펴볼 수 있는 바와 같이, 이러한 팥꽃나무 및 감수의 지용성 성분이 다량 함유되어 있는 팥꽃나무 및 감수 추출물의 분획물은 매우 우수한 효과를 나타낸다.In one embodiment, the red bean and persimmon extract may be a fraction obtained by re-fractionating the organic solvent extract of red bean and persimmon with a second organic solvent. Herein, the organic solvent extract of red bean and persimmon includes all of the oil fraction of red bean and persimmon extract described above, the liquid fraction of red bean and persimmon extract, and the wax fraction of red bean and persimmon extract, By agreement, it refers to the liquid fraction of the red bean and persimmon extracts. Therefore, in one embodiment, the fraction obtained by re-fractionating the organic extract of red bean and persimmon tree with a second organic solvent may mean a fraction obtained by re-fractionating the liquid fraction of red bean and persimmon tree extract with a second organic solvent. have. In another embodiment, the red bean and persimmon extract may be a fraction obtained by re-fractionating a lower alcohol extract of red bean and persimmon with a second organic solvent. In another embodiment, the red bean and persimmon extract may be a fraction obtained by re-fractionating the ethanol extract of red bean and persimmon with hexane. As can be seen in the following examples, the fractions of the red bean and persimmon extracts containing a large amount of fat-soluble components of the red bean and persimmon trees exhibit very excellent effects.
본 명세서에서 팥꽃나무 및 감수를 언급하면서 사용되는 용어 ‘추출물’은 팥꽃나무 및 감수에 추출용매를 처리하여 얻은 조추출물뿐만 아니라 팥꽃나무 및 감수 추출물의 가공물도 포함한다. 예를 들어, 팥꽃나무 및 감수 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The term “extract” used in referring to red bean and persimmon trees in the present specification includes not only crude extract obtained by treating red bean and persimmon with an extraction solvent, but also processed products of red bean and persimmon extract. For example, red bean and persimmon extracts may be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
또한, 본 발명의 팥꽃나무 및 감수 추출물은 광의로는 팥꽃나무 및 감수 자체를 동물에게 투여할 수 있도록 제형화된 팥꽃나무 및 감수 가공물, 예컨대, 팥꽃나무 및 감수 분말도 포함하는 의미를 갖는다. 비록 본 발명에서 팥꽃나무 및 감수 추출물로 실험을 진행하긴 하였으나, 팥꽃나무 및 감수 가공물과 같은 형태로도 목적하는 효과를 달성할 수 있음은 당업자라면 예상 가능할 것이다.In addition, the red bean and persimmon extracts of the present invention have a broad meaning of including red bean and persimmons, such as red bean and persimmon powder, formulated to administer the red bean and persimmon itself to animals. Although the experiment was conducted with the red bean and persimmon extracts in the present invention, it will be expected by those skilled in the art that the desired effect can be achieved even in the same form as the red bean and persimmon tree.
한편, 본 명세서에서 용어 ‘유효성분으로 포함하는’이란 팥꽃나무 및 감수 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 본 발명의 한 구체예에서, 본 발명의 조성물 내에서 팥꽃나무 및 감수 추출물은 예를 들어, 0.001 mg/kg 이상, 바람직하게는 0.1 mg/kg 이상, 보다 바람직하게는 10 mg/kg 이상, 보다 더 바람직하게는 100 mg/kg 포함된다. 팥꽃나무 및 감수 추출물은 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 팥꽃나무 및 감수 추출물의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.
Meanwhile, in the present specification, the term "including as an active ingredient" means including an amount sufficient to achieve the efficacy or activity of the red bean and persimmon extracts. In one embodiment of the present invention, the red bean and persimmon extracts in the composition of the present invention are, for example, 0.001 mg/kg or more, preferably 0.1 mg/kg or more, more preferably 10 mg/kg or more, more More preferably, it contains 100 mg/kg. Since red bean and persimmon extracts are natural products and do not have side effects on the human body even if they are administered in excessive amounts, the upper limit of the quantity of the red bean and persimmon extracts included in the composition of the present invention can be selected and carried out within an appropriate range by a person skilled in the art.
본 발명은 팥꽃나무 및 감수 추출물을 유효성분으로 포함하는 면역기능 증진용 식품 조성물을 제공한다.The present invention provides a food composition for enhancing immune function comprising an red bean and persimmon extract as an active ingredient.
본 발명의 약학 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant includes excipients, disintegrants, sweeteners, binders, coating agents, expanding agents, lubricants, lubricants. Agents or flavoring agents can be used.
상기 약학 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약학 조성물로 바람직하게 제제화할 수 있다. For administration, the pharmaceutical composition may include one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients, and may be preferably formulated into a pharmaceutical composition.
상기 약학 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다. The formulation form of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders are, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, lacquercanth or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. As acceptable pharmaceutical carriers for compositions formulated as liquid solutions, sterilization and biocompatible, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.
본 발명의 약학 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, and the like, preferably oral administration.
본 발명의 약학 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약학 조성물의 1일 투여량은 0.0001-10g/㎏이다.A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, mode of administration, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate and response sensitivity of the patient, and is usually As such, a skilled physician can easily determine and prescribe an effective dosage for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.0001-10g/kg.
본 발명의 약학 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.
The pharmaceutical composition of the present invention is prepared in a unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person having ordinary knowledge in the art Alternatively, it may be manufactured by placing it in a multi-volume container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or a stabilizer.
본 발명은 또한 팥꽃나무 및 감수 추출물을 유효성분으로 포함하는 면역기능 증진용 식품 조성물을 제공한다.The present invention also provides a food composition for improving immune function comprising an red bean and persimmon extract as active ingredients.
본 발명에 따른 식품 조성물은 상기 약학 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.The food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition to be used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gum, ice cream, vitamin complexes, health supplements. Etc.
본 발명의 식품 조성물은 유효성분으로서 팥꽃나무 및 감수 추출물 또는 팥꽃나무 및 감수 분말뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 팥꽃나무 및 감수 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.
The food composition of the present invention may include not only red bean and persimmon extract or red bean and persimmon powder as an active ingredient, but also ingredients commonly added during food production, for example, proteins, carbohydrates, fats, nutrients, It includes seasoning and flavoring agents. Examples of the aforementioned carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is made of drinks and beverages, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts in addition to the red bean and persimmon extracts of the present invention may be additionally included. I can.
본 발명은 상기 팥꽃나무 및 감수 추출물을 유효성분으로 포함하는 면역기능 증진용 식품 조성물을 포함하는 건강기능식품을 제공한다. 건강기능식품이란, 팥꽃나무 및 감수 추출물 또는 팥꽃나무 및 감수 분말을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 팥꽃나무 및 감수 추출물 또는 팥꽃나무 및 감수 분말의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.
The present invention provides a health functional food comprising a food composition for enhancing immune function comprising the red bean and persimmon extracts as active ingredients. Health functional foods are foods prepared by adding red bean and persimmon extract or red bean and persimmon powder to food materials such as beverages, teas, spices, gums, confectionery, etc., or prepared by encapsulation, powdering, suspension, etc. In this case, it means that it has a specific effect on health, but unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long time by using food as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis. The amount of red bean and persimmon extract or red bean and persimmon powder added in such health functional foods cannot be uniformly regulated depending on the type of health functional food, but added within the range that does not damage the original taste of the food. It is sufficient, and is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight, based on the target food. In addition, in the case of health functional foods in the form of pills, granules, tablets or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.
본 발명은 또한 면역기능 증진용 의약 또는 식품의 제조를 위한 팥꽃나무 및 감수 추출물의 용도를 제공한다. 상기한 바와 같이 팥꽃나무 및 감수 추출물 또는 팥꽃나무 및 감수 분말은 면역기능 증강 용도로 이용될 수 있다.The present invention also provides the use of red bean and persimmon extracts for the manufacture of medicines or foods for enhancing immune function. As described above, red bean and persimmon extract or red bean and persimmon powder may be used for enhancing immune function.
또한 본 발명은 포유동물에게 유효량의 팥꽃나무 및 감수 추출물을 투여하는 것을 포함하는 면역기능 촉진 방법을 제공한다.In addition, the present invention provides a method for promoting immune function comprising administering an effective amount of red bean and persimmon extract to a mammal.
여기에서 사용된 용어 "포유동물"은 치료, 관찰 또는 실험의 대상인 포유동물을 말하며, 바람직하게는 인간을 말한다. The term "mammal" as used herein refers to a mammal that is the subject of treatment, observation or experimentation, and preferably refers to a human.
여기에서 사용된 용어 "유효량"은 연구자, 수의사, 의사 또는 기타 임상의에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학적 조성물의 양을 의미하는 것으로, 이는 해당 질환 또는 장애의 증상의 완화를 유도하는 양을 포함한다. 본 발명의 유효 성분에 대한 유효량 및 투여횟수는 원하는 효과에 따라 변화될 것임은 당업자에게 자명하다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다.The term "effective amount" as used herein refers to the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, which is considered by a researcher, veterinarian, doctor or other clinician, Includes an amount that induces relief of symptoms of the disease or disorder. It is apparent to those skilled in the art that the effective amount and the number of administrations for the active ingredient of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered can be easily determined by those skilled in the art, and the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, and general health of the patient. It can be adjusted according to various factors including condition, sex and diet, time of administration, route of administration and secretion rate of the composition, duration of treatment, and drugs used simultaneously.
본 발명의 치료방법에서 팥꽃나무 및 감수 추출물을 유효 성분으로 포함하는 조성물은 경구, 직장, 정맥내, 동맥내, 복강내, 근육내, 흉골내, 경피, 국소, 안구내 또는 피내 경로를 통해 통상적인 방식으로 투여할 수 있다. In the treatment method of the present invention, the composition containing red bean and persimmon extract as active ingredients is conventionally used through oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes. It can be administered in a phosphorus manner.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.
Advantages and features of the present invention, and a method of achieving them will become apparent with reference to embodiments described below in detail. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in a variety of different forms, only the present embodiments are intended to complete the disclosure of the present invention, and the general knowledge in the technical field to which the present invention pertains. It is provided to completely inform the scope of the invention to those who have it, and the invention is only defined by the scope of the claims.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.
Hereinafter, a preferred embodiment is presented to aid the understanding of the present invention, but the following examples are only illustrative of the present invention, and it is obvious to those skilled in the art that various changes and modifications are possible within the scope and spirit of the present invention, It is natural that such modifications and modifications fall within the appended claims.
[[ 실시예Example ]]
실시예Example 1: One: 팥꽃나무Red bean tree 및 감수 복합 추출물의 제조 And production of sensitized complex extract
팥꽃나무 지상부 (분양번호:018-091) 및 감수 (분양번호:CA02-005(2nd)) 추출물은 한국식물추출물은행으로부터 분양을 받아 다양한 비율로 혼합하여 복합 추출물을 제조하였다.
The above-ground part of the red bean tree (pre-sale number: 018-091) and gamsu (pre-sale number: CA02-005 (2nd)) extracts were obtained from Korea Plant Extract Bank and mixed in various ratios to prepare a complex extract.
[[ 실험예Experimental example ]]
실험예Experimental example 1: 면역기능 증진 효과 분석 1: Analysis of immune function enhancement effect
팥꽃나무, 감수 복합물의 면역기능 증진 효과를 분석하기 위하여 식품의약품안전처의 건강기능식품 기능성 평가 가이드에서 제시하는 바이오마커인 IFN-γ 분석을 수행하였다. 팥꽃나무, 감수 복합물이 면역세포의 싸이토카인 생성에 미치는 영향을 확인하기 위해 면역세포주인 NK-92 세포 (입수처: ATCC)를 96-웰 플레이트(well plate)에 20% FCS (Fetal Calf Serum), 1% 안티바이오틱-안티마이코틱 (Antibiotic-antimycotic), 0.2 mM Myo-inositol, 0.1 mM 2-mercaptoethanol, 0.02 mM folic acid 가 첨가된 α-MEM(Minimum Essential Medium)을 사용하여 씨딩(seeding) 하고, 팥꽃나무 샘플을 0, 0.4, 0.8, 1.2 ㎍/㎖ 농도로 처리하고, 감수 샘플을 0, 0.4, 0.8, 1.2 ㎍/㎖ 농도를 추가 처리하여 총 16가지 조합을 37℃ 10% CO2 배양기(Forma Scientific Co., Marjetta, OH, USA)에서 18시간 동안 배양시켰다. 18시간 배양 후 1000rpm, 4분간 원심분리하여 상층액을 획득하였다. In order to analyze the immune function enhancement effect of red bean and persimmon complexes, IFN-γ analysis, a biomarker suggested in the Health Functional Food Functional Evaluation Guide of the Ministry of Food and Drug Safety, was performed. In order to confirm the effect of the red bean and persimmon complex on the cytokine production of immune cells, NK-92 cells (acquired from: ATCC) were added to a 96-well plate with 20% FCS (Fetal Calf Serum), Seeding using α-MEM (Minimum Essential Medium) added with 1% antibiotic-antimycotic, 0.2 mM Myo-inositol, 0.1 mM 2-mercaptoethanol, and 0.02 mM folic acid. , Red bean samples were treated at concentrations of 0, 0.4, 0.8, and 1.2 ㎍/㎖, and sensitized samples were additionally treated with concentrations of 0, 0.4, 0.8, and 1.2 ㎍/㎖, so that a total of 16 combinations were prepared in a 37℃ 10% CO 2 incubator. (Forma Scientific Co., Marjetta, OH, USA) incubated for 18 hours. After incubation for 18 hours, a supernatant was obtained by centrifugation at 1000 rpm for 4 minutes.
획득한 배지를 human IFN-γ Duoset ELISA kit (R&D system)을 활용하여 IFN-γ 생성을 확인한 결과를 도 1에 나타내었다. 이에 따르면, 팥꽃나무 및 감수 복합 추출물이 농도 의존적으로 IFN-γ생성량이 증가하는 것을 확인할 수 있었다.
Fig. 1 shows the results of confirming the production of IFN-γ using the obtained medium using a human IFN-γ Duoset ELISA kit (R&D system). According to this, it was confirmed that the amount of IFN-γ production increased in a concentration-dependent manner in the red bean and persimmon complex extract.
실험예Experimental example 2: 2: 팥꽃나무Red bean tree 및 감수 복합 추출물의 시너지 효과 확인 And synergistic effect of the sensitization complex extract
실험예 1에서의 실험 결과를 바탕으로, CompuSyn software (ComboSyn, Inc., USA)를 통해 Combination Index (CI)를 계산하여 그 결과를 도 2 및 도 3에 나타내었다. 이에 따르면, 팥꽃나무 추출물과 감수 추출물의 복합 추출물의 면역증진 상승효과(Synergism)를 확인할 수 있었다. 계산된 CI 값에 따라 모든 농도에서 팥꽃나무 및 감수 복합 추출물의 상승효과가 확인되었으며, 특히 팥꽃나무(1.2 ㎍/㎖)+감수(0.8 ㎍/㎖) 복합물에서는 강한 상승효과(Strong synergism), 팥꽃나무(1.2 ㎍/㎖)+감수(1.2 ㎍/㎖) 복합물에서는 매우 강한 상승효과(Very strong synergism)을 확인할 수 있었다.
Based on the experimental results in Experimental Example 1, Combination Index (CI) was calculated through CompuSyn software (ComboSyn, Inc., USA), and the results are shown in FIGS. 2 and 3. According to this, it was possible to confirm the synergism of the complex extract of red bean extract and persimmon extract. According to the calculated CI value, the synergistic effect of the red bean and persimmon complex extract was confirmed at all concentrations. In particular, strong synergism, red bean in the complex of red bean (1.2 ㎍/㎖) + persimmon tree (0.8 ㎍/㎖) Very strong synergism was observed in the flower tree (1.2 ㎍/㎖) + gamsu (1.2 ㎍/㎖) complex.
이상, 본 발명의 실시예들에 대하여 설명하였으나, 해당 기술 분야에서 통상의 지식을 가진 자라면 특허청구범위에 기재된 본 발명의 사상으로부터 벗어나지 않는 범위 내에서, 구성 요소의 부가, 변경, 삭제 또는 추가 등에 의해 본 발명을 다양하게 수정 및 변경시킬 수 있을 것이며, 이 또한 본 발명의 권리범위 내에 포함된다고 할 것이다.In the above, embodiments of the present invention have been described, but those of ordinary skill in the art will add, change, delete or add components within the scope not departing from the spirit of the present invention described in the claims. Various modifications and changes can be made to the present invention by means of the like, and it will be said that this is also included within the scope of the present invention.
Claims (16)
상기 팥꽃나무 및 감수 복합 추출물은 팥꽃나무 및 감수를 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출한 것을 특징으로 하는 면역기능 증진용 약학 조성물.The method of claim 1,
The red bean and persimmon complex extract is a pharmaceutical composition for enhancing immune function, characterized in that the red bean and persimmon are extracted with water, alcohol having 1-4 carbon atoms, or a mixed solvent thereof.
상기 팥꽃나무 추출물은 팥꽃나무의 줄기 및 뿌리 중에서 선택된 1종 이상의 추출물인 것을 특징으로 하는 면역기능 증진용 약학 조성물. The method of claim 2,
The red bean extract is a pharmaceutical composition for improving immune function, characterized in that at least one extract selected from the stem and root of the red bean.
상기 감수 추출물은 감수의 뿌리 추출물인 것을 특징으로 하는 면역기능 증진용 약학 조성물.The method of claim 2,
The persimmon extract is a pharmaceutical composition for improving immune function, characterized in that the root extract of persimmon.
상기 팥꽃나무 및 감수 복합 추출물은 팥꽃나무 추출물 100중량부에 대하여 감수 추출물 50 내지 200중량부를 포함하는 것을 특징으로 하는 면역기능 증진용 약학 조성물.The method of claim 1,
The red bean and persimmon complex extract is a pharmaceutical composition for improving immune function, characterized in that it comprises 50 to 200 parts by weight of persimmon extract based on 100 parts by weight of red bean extract.
상기 팥꽃나무 및 감수 복합 추출물은 팥꽃나무 및 감수를 물, 탄소수 1-4의 알코올, 또는 이들의 혼합용매에 의해 추출한 것을 특징으로 하는 면역기능 증진용 식품 조성물.The method of claim 6,
The red bean and persimmon complex extract is a food composition for improving immune function, characterized in that the red bean and persimmon were extracted with water, alcohol having 1-4 carbon atoms, or a mixed solvent thereof.
상기 팥꽃나무 추출물은 팥꽃나무의 줄기 및 뿌리 중에서 선택된 1종 이상의 추출물인 것을 특징으로 하는 면역기능 증진용 식품 조성물. The method of claim 7,
The red bean extract is a food composition for improving immune function, characterized in that at least one extract selected from the stem and root of red bean.
상기 감수 추출물은 감수의 뿌리 추출물인 것을 특징으로 하는 면역기능 증진용 식품 조성물.The method of claim 7,
The persimmon extract is a food composition for improving immune function, characterized in that the root extract of persimmon.
상기 팥꽃나무 및 감수 복합 추출물은 팥꽃나무 추출물 100중량부에 대하여 감수 추출물 50 내지 200중량부를 포함하는 것을 특징으로 하는 면역기능 증진용 식품 조성물.The method of claim 6,
The red bean and persimmon complex extract is a food composition for improving immune function, characterized in that it comprises 50 to 200 parts by weight of persimmon extract based on 100 parts by weight of red bean extract.
상기 팥꽃나무는 팥꽃나무의 줄기 및 뿌리 중에서 선택된 1종 이상의 부위를 사용하는 것을 특징으로 하는 면역기능 증진용 약학 조성물의 제조방법. The method of claim 11,
The method for producing a pharmaceutical composition for improving immune function, characterized in that the red bean tree uses one or more parts selected from the stem and root of the red bean flower tree.
상기 감수는 감수의 뿌리 부위를 사용하는 것을 특징으로 하는 면역기능 증진용 약학 조성물의 제조방법.The method of claim 11,
The method of manufacturing a pharmaceutical composition for improving immune function, characterized in that the gamsu uses a root portion of gamsu.
상기 팥꽃나무는 팥꽃나무의 줄기 및 뿌리 중에서 선택된 1종 이상의 부위를 사용하는 것을 특징으로 하는 면역기능 증진용 식품 조성물의 제조방법. The method of claim 14,
The red bean flower tree is a method for producing a food composition for improving immune function, characterized in that using one or more parts selected from the stem and root of the red bean flower tree.
상기 감수는 감수의 뿌리 부위를 사용하는 것을 특징으로 하는 면역기능 증진용 식품 조성물의 제조방법.The method of claim 14,
The method of manufacturing a food composition for improving immune function, characterized in that the gamsu uses the root portion of gamsu.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190027981A KR20200109026A (en) | 2019-03-12 | 2019-03-12 | COMPOSITION FOR IMPROVING IMMUNITY FUNCTION COMPRISING Daphne genkwa AND Euphorbiakansui Liou ex Wanga COMPLEX EXTRACT AS AN EFFECTIVE INGREDIENT |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190027981A KR20200109026A (en) | 2019-03-12 | 2019-03-12 | COMPOSITION FOR IMPROVING IMMUNITY FUNCTION COMPRISING Daphne genkwa AND Euphorbiakansui Liou ex Wanga COMPLEX EXTRACT AS AN EFFECTIVE INGREDIENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200109026A true KR20200109026A (en) | 2020-09-22 |
Family
ID=72706734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190027981A KR20200109026A (en) | 2019-03-12 | 2019-03-12 | COMPOSITION FOR IMPROVING IMMUNITY FUNCTION COMPRISING Daphne genkwa AND Euphorbiakansui Liou ex Wanga COMPLEX EXTRACT AS AN EFFECTIVE INGREDIENT |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20200109026A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022119077A1 (en) * | 2020-12-03 | 2022-06-09 | 필리아바이오 주식회사 | Animal feed additive containing daphne genkwa callus or seedlings as active ingredient |
| WO2022119078A1 (en) * | 2020-12-03 | 2022-06-09 | 필리아바이오 주식회사 | Antiviral composition containing daphne genkwa callus as active ingredient |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101364234B1 (en) | 2011-05-17 | 2014-02-17 | 한국생명공학연구원 | Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising the extract Daphne genkwa, fraction of thereof or compound isolated therefrom as an active ingredient |
-
2019
- 2019-03-12 KR KR1020190027981A patent/KR20200109026A/en active Search and Examination
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101364234B1 (en) | 2011-05-17 | 2014-02-17 | 한국생명공학연구원 | Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising the extract Daphne genkwa, fraction of thereof or compound isolated therefrom as an active ingredient |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022119077A1 (en) * | 2020-12-03 | 2022-06-09 | 필리아바이오 주식회사 | Animal feed additive containing daphne genkwa callus or seedlings as active ingredient |
| WO2022119078A1 (en) * | 2020-12-03 | 2022-06-09 | 필리아바이오 주식회사 | Antiviral composition containing daphne genkwa callus as active ingredient |
| KR20220078272A (en) * | 2020-12-03 | 2022-06-10 | 필리아바이오 주식회사 | Antivirus composition comprising daphne genkwa callus |
| KR20230070172A (en) * | 2020-12-03 | 2023-05-22 | 필리아바이오 주식회사 | Antivirus composition comprising daphne genkwa callus |
| KR20230070171A (en) * | 2020-12-03 | 2023-05-22 | 필리아바이오 주식회사 | Antivirus composition comprising daphne genkwa callus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3193898B1 (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| KR101751398B1 (en) | Composition comprising Angelica gigas Nakai, Cornus officinalis, Cervi Parvum Cornu, Red ginseng, Rehmanniae Radix Preparata, Aquilaria agallocha Roxburgh and Honey for anti-inflammation | |
| KR20200109026A (en) | COMPOSITION FOR IMPROVING IMMUNITY FUNCTION COMPRISING Daphne genkwa AND Euphorbiakansui Liou ex Wanga COMPLEX EXTRACT AS AN EFFECTIVE INGREDIENT | |
| KR20180011021A (en) | Pharmaceutical composition comprising extract of Clematis apiifolia DC. or Silene armeria L. for treating or prventing inflammatory disease | |
| KR102086166B1 (en) | Antimicrobial composition comprising the extracts of rambutan peel | |
| KR102483928B1 (en) | Composition For Improving Fatigue Including Antler And Angelica | |
| KR101384633B1 (en) | A composition for treating or preventing toxoplasmosis comprising Zingiber officinale extract and fractions thereof | |
| KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
| KR101919161B1 (en) | Composition for improving condition of hair and preventing hair loss | |
| KR101760163B1 (en) | Composition for anti-obesity comprising extract of Sargassum serratifolium as an effective component | |
| KR102204912B1 (en) | Pharmaceutical Composition Comprising Fraction of Ginseng Extract for Preventing or Treating Liver Diseases | |
| KR101938055B1 (en) | A composition for treating, improving and preventing of artheriosclerosis comprising Gracilariopsis chorda ohmi extract or Gracilariopsis chorda ohmi fraction | |
| KR101077916B1 (en) | Pharmaceutical compositions for prevention and treatment of obesity comprising extract of eremochloa ophiuroides as an active ingredient | |
| KR101724587B1 (en) | Composition for treating, improving or preventing liver injury and liver dysfunction | |
| KR101894156B1 (en) | Method for producing codonopsis lanceolata extract and uses thereof | |
| KR20200069616A (en) | Anti-inflammatory composition comprising Prunus pendula for. ascendens (Makino) Ohwi | |
| KR20140083493A (en) | Composition for anti-obesity comprising extract of Sargassum fulvellum or Sargassum horneri as an effective component | |
| KR20130094553A (en) | Food composition, pharmaceutical composition and animal medicine against cancer containing gingerenone a | |
| KR20190086961A (en) | Composition for enhancing immune response comprising an extract of chinese herb as an effective ingredient | |
| KR102092961B1 (en) | Pharmaceutical composition comprising the ethanol extract of abeliophyllum distichum as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
| KR101923822B1 (en) | Anti-inflammatory composition containing extract of cornus officinalis seed | |
| KR20230076953A (en) | Antiviral composition comprising extract of Oenothera biennis L. | |
| KR20230104443A (en) | Use of a composition comprising glutinous foxtail millet extract or a fraction thereof for preventing, improving or treating sarcopenia | |
| KR20230093679A (en) | Composition comprising extract of Kadsura japonica for anti-obesity | |
| KR20230119507A (en) | A Pharmaceutical Composition For Preventing Or Treating Bone Disease Comprising Cuscuta Australis Seed Extract And Caragana Sinica Extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination |